Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

16 April 2022: Articles  Czech Republic

Histiocytic Sarcoma with an Unusual Clinical Manifestation Imitating Malignant Vascular Tumor: A Case Report

Unknown etiology, Unusual clinical course, Challenging differential diagnosis, Rare disease

Róbert Ondruššek12CE*, Jana Žmolíková3D, Jarmila Šimová3E, Petra Bartová45B, Pavel Hurník34B, Magdalena Uvírová34B, Dušan Žiak34E

DOI: 10.12659/AJCR.935824

Am J Case Rep 2022; 23:e935824

0 Comments

Abstract

BACKGROUND: Histiocytic sarcoma is a rare malignant hematopoietic neoplasm with morphologic and immunohistochemical features of histiocytic differentiation, usually with unfavorable prognosis. Despite aggressive biological behavior, in subgroup of patients with localized disease, the prognosis can be very good. Few publications are available on localized cases of histiocytic sarcoma. These occur infrequently and continue to be a poorly-recognized morphological entity.

CASE REPORT: A 73-year old man treated for Parkinson syndrome presented with a tumor resistance on the dorsal surface of the left forearm. This lesion was clinically seen as an organized hematoma and was surgically resected. Histologically, the tumor was situated in the dermis and subcutis and it consisted of multiple neoplastic nodules. Vasoformative growth patterns with the vascular-like spaces containing erythrocytes and hemosiderin pigment presence simulated the morphology of angiosarcoma. Based on the immunohistochemical characteristics, we diagnosed the tumor as cutaneous histiocytic sarcoma. Genetic analysis revealed immunoglobulin heavy-chain gene rearrangement without any concomitant hematological malignancy. The patient demonstrated no systemic disease or impairment associated with diagnosed histiocytic sarcoma, and no recurrence has been found to date.

CONCLUSIONS: We report a case of primary cutaneous histiocytic sarcoma with an excellent outcome after surgical treatment only. Clinical data and histopathological and immunohistochemical evaluation were essential to rule out other malignant tumors in the differential diagnosis. Genetic analysis together with up-to-date knowledge and understanding of principles of tumorous transformations helped to diagnose this poorly-recognized entity with various clinical behaviors.

Keywords: Diagnosis, Histiocytic Sarcoma, Histology

Background

Histiocytic sarcoma (HS) is a rare malignant tumor accounting for less than 1% of all hematological neoplasms [1]. The typical histiocytic differentiation is usually found at extranodal sites, including skin, gastrointestinal tract, soft tissues, and other organs, and, very rarely, in the pericardium [2]. These tumors can occur in wide age range, with an average age of 52 years, with a male predilection according to some studies [3]. The etiology and pathogenesis are unknown. The literature reports presumed transdifferentiation of a preexisting hematolymphoid disorder in approximately 25% of the cases [4–6]. Localized disease of skin and connective soft tissue has a better prognosis with a longer overall survival in patients receiving only surgical therapy. Disseminated disease with involvement of hematopoietic organs usually has poor outcome, despite available chemotherapy. The present case of localized cutaneous histiocytic sarcoma had an excellent prognosis. Also, we would like to demonstrate the diagnostic challenge undertaken here to specify the diagnosis and to distinguish from other vascular malignancies known to have more aggressive behavior.

Case Report

A 73-year-old man had been treated for Parkinson syndrome with antiparkinsonian therapy (L-DOPA) since 1999. He received surgical deep brain stimulation for impaired body motion and late complications of movement disorder as part of neurological treatment in 2008. He had been treated for psoriasis vulgaris and had nasal barriers for repair of a deviated nasal septum. He was trained as an electrician in his younger years and later he also worked as a gardener and inspection technician. No allergies were reported. His family history revealed his father had neurological impairment of fine movement-shaking disturbances and he died of non-specified gastric complications. Mother was treated for bowel cancer and died of complications related to a fractured femoral neck. The patient’s current disease started when he reported a lump on the dorsal surface of the left forearm. He has noticed this skin resistance first 9 months before going to the doctor’s office. The tumor was 5 cm in diameter and was clinically assessed as an organized hematoma. The lesion was surgically resected in December 2019. There were no need for re-excision, as the surgical margins were tumor-free when we performed histopathological examination of this specimen. Macroscopically, the tumor appeared to be fairly localized, of firm consistency, and discolored yellow-to-grey. Microscopically, the tumor in the dermis and subcutis consisted of multiple neoplastic nodules separated with fibrous septa. There were also reticular and vasoformative growth patterns, numerous areas with vascular-like spaces filled with erythrocytes (Figure 1A). Within solid parts, cord-like changes were present and there were deposits of hemosiderin-laden macrophages (siderophages) in fibrous neoplastic stroma within the tumor (Figure 1B). The neoplastic cells were monomorphic with occasional round-to-oval larger cells with abundant eosinophilic cytoplasm (Figure 1C, marked by blue arrows) and with osteoclast-like cells (Figure 1C, marked by yellow arrows). Some of neoplastic nuclei showed irregular folds. Occasional hemophagocytosis was spotted (Figure 1D). Adjacent mild inflammatory infiltrate consisting of lymphocytes was seen. The featured hemosiderin pigment and the above-mentioned growth patterns simulated the morphology of angiosarcoma. Based on the extensive immunohistochemical evaluation, we made a diagnosis of histiocytic sarcoma. Histiocytic markers CD68 a CD163, LCA, CD45RO, CD4, and lysozyme were expressed by the tumor. All other markers – CK AE1/3, CK5/6, CD3, CD20, CD23, CD1a, CD34, ERG, factor VIII, CD30, CD117, CD99, S100, PAX5, SOX10, smooth muscle actin, EMA, caldesmon H, desmin, thyroglobulin and melanocyte markers – were negative. Proliferative activity in Ki67 (mitotic index) was around 15%. Histopathological assessment was complimented by genetic testing. FISH (fluorescence in situ hybridization) demonstrated an immunoglobulin heavy-chain (IgH) gene rearrangement (Figure 2). We also analyzed the BRAF gene mutation involving codon V600 and K601 by reverse hybridization (using the BRAF 600/601 StripAssay® kit) and these were not identified here. No radiotherapy was required after surgical resection. Results of a complete blood count were normal and further oncology follow-up showed no additional systemic disease and no recurrence. The patient appears to be disease-free to date, 26 months after completion of surgical resection.

Discussion

By definition, HS is a malignant proliferation of cells demonstrating pathological and immunohistochemical signs of mature tissue histiocytes with expression of 1 or more histiocytic markers, including CD68, lysozyme, and CD163, with absence of Langerhans cells, follicular dendritic cells, and myeloid cell markers [3]. HS usually lacks clonal IgH and TCRγ rearrangements [3], but rare cases have been reported showing antigen receptor gene rearrangements, most likely representing cases of transdifferentiation. The available data explains the occurrence of 2 hematological malignances as a result of transdifferentiation allowing 2 hematopoietic populations in the same patient sharing identical genetic abnormalities, increasing the possibility that tumors expressing the phenotype of 1 hematopoietic lineage might “transdifferentiate” into a genetically analogous but phenotypically distinct tumor [4–6]. This process is very interesting and is not fully explained. A subgroup of these cases of HS may be associated with IgH gene rearrangement [5]. Studies proved this association, mainly among HS and B-follicular lymphomas (B-FL) [5], but also with MALT lymphoma [6], CLL/SLL, and lymphoblastic leukemia [7]. An interesting study reported a group of 8 patients with both B-FL and H/DC (histiocytic/dendritic cell) tumors, where the IgH gene rearrangement was noted in 4 cases of HS of skin and soft tissues diagnosed by PCR and FISH [5]. Other conditions associated with HS include myelodysplasia [3,8] and leukemia. In our case, FISH was used to identify the IgH gene rearrangement. As mentioned above, clinical hematology/oncology evaluation showed no evidence of the disease. A subset of described cases of HS occur in patients with nonseminomatous mediastinal germ cell tumors [9], and localized cutaneous HS can be associated with previous trauma [10]. Radiation was a risk factor for etiopathogenesis of HS in a case with a history of recurrent pineal cavernous hemangioma of the CNS [11]. A subset of cases with clinically localized disease of skin or soft tissues have good long-term outcome and better prognosis compared to other extranodal locations, similar to our case [12–15]. A very important prognostic factor is the tumor size, as larger tumors usually have a worse prognosis [4,12,16]. Hornick et al investigated 14 cases of extranodal HS, in which the patients with poor outcome had the largest primary tumors [16]. The age of patients can be independent prognostic factor, with younger patients expected to have better disease outcomes [12,17]. In general, surgery, chemotherapy, and radiotherapy are therapeutic modalities of choice. The treatment relies on surgical resection with wide surgical margins and complete resection is important for curability [12]. Radiotherapy seems to be more important as an adjunctive in management of tumors where complete surgical resection cannot be achieved. Chemotherapy regimens are more controversial and limited [18]. HS with systemic involvement has very poor prognosis despite aggressive chemotherapy [4,17,19]. Thalidomide, along with autologous or allogeneic stem cell transplant, has been recently shown to be of benefit for several patients with HS [20,21]. An interesting and promising target therapy is use of a BRAF inhibitor in cases of HS showing BRAF V600E mutation [22,23]. Other HS treatment targets include immune checkpoint pathways such as PD-1 and PD-L1 [23–25].

Conclusions

Localized extranodal cutaneous histiocytic sarcoma is an uncommon and unique malignancy with specific histopathological features and genetic characteristics. It is important to distinguish this rare entity from conditions mimicking angiosarcoma and malignant vascular tumors. The surgical resection provided clear specimen margins confirmed by histology, which has prognostic importance and makes surgery a possible curable approach, particularly in patients with localized HS. This strongly suggests the existence of a group of curable patients with excellent prognosis. IgH gene rearrangement may be associated with the development of another hematological malignancy; therefore, patients should be carefully monitored.

References:

1.. Dalia S, Shao H, Sagatys E, Dendritic cell and histiocytic neoplasms: Biology, diagnosis, and treatment: Cancer Control, 2014; 21; 290-300

2.. Dong A, Wang Y, Cui Y, Enhanced CT and FDG PET/CT in histiocytic sarcoma of the pericardium: Clin Nucl Med, 2016; 41; 326-27

3.. Swerdlow H, Campo E, Harris NL: WHO classification of tumours of haematopoietic and lymphoid tissues, 2017; 468-70

4.. Andersen KF, Sjö LD, Kampmann P, Histiocytic sarcoma: Challenging course, dismal outcome: Diagnostics (Basel), 2021; 11; 310

5.. Feldman AL, Arber DA, Pittaluga S, Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: Evidence for transdifferentiation of the follicular lymphoma clone: Blood, 2008; 111(12); 5433-39

6.. Alvaro T, Bosch R, Salvadó MT, True histiocytic lymphoma of the stomach associated with low-grade B-cell mucosa-associated lymphoid tissue (MALT)-type lymphoma: Am J Surg Pathol, 1996; 20(11); 1406-11

7.. Feldman AL, Berthold F, Arceci RJ, Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis: Lancet Oncol, 2005; 6(6); 435-37

8.. Sohn BS, Kim T, Kim JE, A case of histiocytic sarcoma presenting with primary bone marrow involvement: J Korean Med Sci, 2010; 25; 313-16

9.. deMent SH, Association between mediastinal germ cell tumors and hematologic malignancies: An update: Hum Pathol, 1990; 21; 699-703

10.. Zafar A, Hanif F, Unusual presentation of a rare tumor: Histiocytic sarcoma presenting as a finger growth: Cureus, 2019; 11(11); e6150

11.. Wu W, Tanrivermis Sayit A, Vinters HV, Primary central nervous system histiocytic sarcoma presenting as a postradiation sarcoma: Case report and literature review: Hum Pathol, 2013; 44(6); 1177-83

12.. Sato N, Arai E, Nakamura Y, Primary cutaneous localized/clearly-outlined true histiocytic sarcoma: Two long-term follow-up cases: J Dermatol, 2020; 47; 651-53

13.. Jiang QM, Zhou WW, Song R, [Histiocytic sarcoma: Clinicopathologic study of 4 cases.]: Zhonghua Xue Ye Xue Za Zhi, 2012; 33(9); 751-55 [in Chinese]

14.. Zheng YY, Zhou XG, Zhang SH, [Histiocytic sarcoma: A clinicopatho-logical study of 6 cases.]: Zhonghua Bing Li Xue Za Zhi Feb, 2010; 39(2); 79-83 [in Chinese]

15.. Trevisan F, Xavier CA, Pinto CA, Case report of cutaneous histiocytic sarcoma: Diagnostic and therapeutic dilemmas: An Bras Dermatol, 2013; 88(5); 807-10

16.. Hornick JL, Jaffe ES, Fletcher CD, Extranodal histiocytic sarcoma: Clinicopathologic analysis of 14 cases of a rare epithelioid malignancy: Am J Surg Pathol, 2004; 28(9); 1133-44

17.. Ajabnoor R, Bell PD, Schiffman S, Histiocytic sarcoma arising from a long bone: Report of two cases: Int J Surg Pathol, 2021; 29; 752-58

18.. Aytekin A, Ozet A, Bilgetekin I, A metastatic histiocytic sarcoma case with primary involment of the tonsil: J Cancer Res Ther, 2020; 16(3); 665-67

19.. Saboo S, Krajewski KM, Shinagare AB, Imaging features of primary extranodal histiocytic sarcoma: Report of two cases and a review of the literature: Cancer Imaging, 2012; 12(1); 253-58

20.. Gergis U, Dax H, Ritchie E, Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: A case report and review of the literature: J Clin Oncol, 2011; 29; e251-3

21.. Abidi MH, Tove I, Ibrahim RB, Maria D, Peres E, Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant: Am J Hematol, 2007; 82; 932-33

22.. Idbaih A, Mokhtari K, Emile J-F, Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib: Neurology, 2014; 83; 1478-80

23.. Gatalica Z, Bilalovic N, Palazzo JP, Disseminated histiocytoses bio-markers beyond BRAFV600E: frequent expression of PD-L1: Oncotarget, 2015; 6(23); 19819-25

24.. Tsirigotis P, Savani BN, Nagler A, Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies: Ann Med, 2016; 48; 428-39

25.. Facchetti F, Pileri SA, Lorenzi L, Histiocytic and dendritic cell neoplasms: What have we learned by studying 67 cases: Virchows Arch, 2017; 471; 467-89

SARS-CoV-2/COVID-19

16 June 2022 : Case report  Ecuador

Multidrug-Resistant Klebsiella pneumoniae in a Patient with SARS-Cov-2 Pneumonia in an Intensive Care Unit ...

Am J Case Rep In Press; DOI: 10.12659/AJCR.936498  

13 June 2022 : Case report  Japan

Stenotrophomonas maltophilia Infection Associated with COVID-19: A Case Series and Literature Review

Am J Case Rep In Press; DOI: 10.12659/AJCR.936889  

13 June 2022 : Case report  Saudi Arabia

Atlantoaxial Subluxation Secondary to SARS-CoV-2 Infection: A Rare Orthopedic Complication from COVID-19

Am J Case Rep In Press; DOI: 10.12659/AJCR.936128  

03 June 2022 : Case report  Japan

Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series

Am J Case Rep In Press; DOI: 10.12659/AJCR.936832  

In Press

24 Jun 2022 : Case report  USA

A 24-Year-Old Man Presenting with Lung Metastases from a Primary Retroperitoneal Extragonadal Choriocarcinoma

Am J Case Rep In Press; DOI: 10.12659/AJCR.936288  

24 Jun 2022 : Case report  Romania

Odontogenic Keratocyst: The Dos and Don’ts in a Clinical Case Scenario

Am J Case Rep In Press; DOI: 10.12659/AJCR.936641  

24 Jun 2022 : Case report  Saudi Arabia

Management of Patients with Alagille Syndrome Undergoing Living Donor Liver Transplantation: A Report of 2 ...

Am J Case Rep In Press; DOI: 10.12659/AJCR.936513  

22 Jun 2022 : Case report  USA

A Case of Lymphomatoid Granulomatosis in a Lymph Node with Unique Clinical and Histopathologic Features

Am J Case Rep In Press; DOI: 10.12659/AJCR.936862  

Most Viewed Current Articles

23 Feb 2022 : Case report  USA

Penile Necrosis Associated with Local Intravenous Injection of Cocaine

DOI :10.12659/AJCR.935250

Am J Case Rep 2022; 23:e935250

17 Feb 2022 : Case report  Oman

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of P...

DOI :10.12659/AJCR.934399

Am J Case Rep 2022; 23:e934399

06 Dec 2021 : Case report  Brazil

Lipedema Can Be Treated Non-Surgically: A Report of 5 Cases

DOI :10.12659/AJCR.934406

Am J Case Rep 2021; 22:e934406

09 Feb 2022 : Case report  Saudi Arabia

Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COV...

DOI :10.12659/AJCR.934744

Am J Case Rep 2022; 23:e934744

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923